^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 overexpression

    i
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (CHECK'UP) (NCT03412058)
    Phase N/A
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/27/2018
    Primary completion :
    01/02/2024
    Completion :
    12/01/2025
    EGFR • ALK
    |
    PD-L1 expression • PD-L1 overexpression • ALK negative
    Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (SWOG S1609) (NCT02834013)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/30/2017
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    CD4
    |
    PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088
    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667)
    Phase 2
    ImmunityBio, Inc.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/11/2018
    Primary completion :
    08/31/2029
    Completion :
    12/31/2030
    BRAF • ALK • MSI
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (NCT04585477)
    Phase 2
    Stanford University
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/08/2021
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    PD-L1 • ALK • ROS1
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel
    Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (KEYNOTE-C62) (NCT05860296)
    Phase 1/2
    SignalChem Lifesciences Corporation
    Recruiting
    Last update posted :
    11/19/2024
    Initiation :
    05/31/2023
    Primary completion :
    09/01/2026
    Completion :
    09/01/2028
    PD-L1 • KRAS • ALK • ROS1
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • SLC-391
    A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors (KEYNOTE-A87) (NCT03565445)
    Phase 1
    Astellas Pharma Global Development, Inc.
    Completed
    Last update posted :
    11/01/2024
    Initiation :
    07/02/2018
    Primary completion :
    03/27/2023
    Completion :
    03/27/2023
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
    Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (NCT04736173)
    Phase 3
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    02/08/2021
    Primary completion :
    08/31/2024
    Completion :
    07/01/2027
    PD-L1
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154) • mitazalimab (ADC-1013)
    Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) (NCT04262856)
    Phase 2
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    05/28/2020
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    PD-L1
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)
    Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial (NCT03801902)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    10/28/2019
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    PD-L1 • CD4
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients. (POLARIS) (NCT03433924)
    Phase N/A
    AstraZeneca
    Completed
    Last update posted :
    03/27/2024
    Initiation :
    05/18/2020
    Primary completion :
    03/27/2023
    Completion :
    03/27/2023
    PD-L1 • CD8
    |
    PD-L1 expression • PD-L1 overexpression
    Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen (NCT06036745)
    Phase 2
    Shanghai Minimally Invasive Surgery Center
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    07/01/2022
    Primary completion :
    07/01/2023
    Completion :
    07/01/2026
    PD-L1 • TMB • MSI
    |
    TMB-H • MSI-H/dMMR • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • oxaliplatin
    Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer (NCT05340309)
    Phase 2
    University of Southern California
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    12/07/2022
    Primary completion :
    12/07/2025
    Completion :
    12/07/2026
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer. (ANV419-001) (NCT04855929)
    Phase 1
    Anaveon AG
    Recruiting
    Last update posted :
    02/12/2024
    Initiation :
    05/25/2021
    Primary completion :
    09/01/2024
    Completion :
    01/01/2025
    PD-L1
    |
    PD-L1 overexpression
    |
    Yervoy (ipilimumab) • ANV419
    A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal) (NCT03782207)
    Phase N/A
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/01/2024
    Initiation :
    02/07/2019
    Primary completion :
    07/31/2026
    Completion :
    07/31/2026
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
    |
    Tecentriq (atezolizumab)
    Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278)
    Phase 1
    Rutgers, The State University of New Jersey
    Completed
    Last update posted :
    12/06/2023
    Initiation :
    10/03/2017
    Primary completion :
    10/20/2022
    Completion :
    10/30/2022
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • troriluzole (BHV-4157)
    PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer (NCT05732948)
    Phase 1
    Shanghai Unicar-Therapy Bio-medicine Technology...
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    08/02/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PD-L1 • PSCA
    |
    PD-L1 expression • PD-L1 overexpression
    |
    cyclophosphamide
    Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression. (EXPLORE-PDL1) (NCT02785562)
    Phase N/A
    Groupe Francais De Pneumo-Cancerologie
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    07/21/2016
    Primary completion :
    04/06/2020
    Completion :
    04/06/2020
    CD8
    |
    PD-L1 expression • PD-L1 overexpression • PD-L1 negative
    |
    cisplatin
    A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) (NCT03679767)
    Phase 2
    Incyte Corporation
    Completed
    Last update posted :
    07/21/2023
    Initiation :
    01/09/2019
    Primary completion :
    04/15/2021
    Completion :
    06/28/2022
    PD-L1 • ALK
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Zynyz (retifanlimab-dlwr)
    This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (NCT03156114)
    Phase 1
    Boehringer Ingelheim
    Completed
    Last update posted :
    06/29/2023
    Initiation :
    06/13/2017
    Primary completion :
    03/09/2023
    Completion :
    06/06/2023
    EGFR • ALK • TMB • MSI
    |
    PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type
    |
    ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer (SHARP) (NCT05701176)
    Phase N/A
    Amsterdam UMC, location VUmc
    Recruiting
    Last update posted :
    01/27/2023
    Initiation :
    11/03/2022
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    EGFR • PD-L1 • ALK
    |
    PD-L1 expression • PD-L1 overexpression • ALK mutation • EGFR negative
    Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC (NCT05394233)
    Phase 2
    Sichuan Cancer Hospital and Research Institute
    Not yet recruiting
    Last update posted :
    05/27/2022
    Initiation :
    06/01/2022
    Primary completion :
    12/01/2023
    Completion :
    06/01/2024
    EGFR
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion
    |
    Avastin (bevacizumab) • cisplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed
    Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME) (NCT03709147)
    Phase 2
    Marina Garassino
    Recruiting
    Last update posted :
    11/16/2020
    Initiation :
    10/30/2018
    Primary completion :
    09/10/2023
    Completion :
    09/10/2023
    ALK • ROS1 • STK11 • IGF1
    |
    PD-L1 overexpression • ALK rearrangement • ROS1 rearrangement • STK11 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • metformin
    Texture Features and PDL1 in CT-PET 18 FDG (NCT04309422)
    Phase N/A
    University Hospital, Montpellier
    Completed
    Last update posted :
    03/18/2020
    Initiation :
    04/01/2018
    Primary completion :
    10/01/2018
    Completion :
    01/31/2020
    PD-L1
    |
    PD-L1 overexpression
    A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer (NCT02840994)
    Phase 1
    Bavarian Nordic
    Completed
    Last update posted :
    02/27/2020
    Initiation :
    12/01/2016
    Primary completion :
    01/01/2020
    Completion :
    01/01/2020
    ALK • ROS1 • CEACAM5
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Panvac-VF (falimarev/inalimarev)
    Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer (NCT03495544)
    Phase N/A
    Tatarstan Cancer Center
    Unknown status
    Last update posted :
    04/12/2018
    Initiation :
    01/01/2018
    Primary completion :
    03/17/2019
    Completion :
    07/01/2019
    HER-2
    |
    PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression • PD-L1-L